Search Results - "NEHMIZ, Gerhard"

Bayesian Phase II optimization for time-to-event data based on historical information by Bertsche, Anja, Fleischer, Frank, Beyersmann, Jan, Nehmiz, Gerhard

“…After exploratory drug development, companies face the decision whether to initiate confirmatory trials based on limited efficacy information. This…”
Get full text

Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study) by Ezekowitz, Michael D., MD, PhD, Reilly, Paul A., PhD, Nehmiz, Gerhard, PhD, Simmers, Timothy A., MD, Nagarakanti, Rangadham, MD, Parcham-Azad, Kambiz, MD, Pedersen, K. Erik, MD, Lionetti, Dominick A., MA, Stangier, Joachim, PhD, Wallentin, Lars, MD, PhD

“…This is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with atrial fibrillation (AF). Patients (n = 502) were randomized to…”
Get full text

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects by Seman, Leo, Macha, Sreeraj, Nehmiz, Gerhard, Simons, Gudrun, Ren, Bailuo, Pinnetti, Sabine, Woerle, Hans J., Dugi, Klaus

“…Empagliflozin is an orally available, selective inhibitor of sodium glucose cotransporter 2. In this study, single oral doses of empagliflozin from 0.5 to 800…”
Get full text

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients by Hinrichsen, Holger, Benhamou, Yves, Wedemeyer, Heiner, Reiser, Markus, Sentjens, Roel E., Calleja, José L., Forns, Xavier, Erhardt, Andreas, Crönlein, Jens, Chaves, Ricardo L., Yong, Chan-Loi, Nehmiz, Gerhard, Steinmann, Gerhard G.

“…Background & Aims: Novel, potent, and well-tolerated hepatitis C virus (HCV) drugs are needed. BILN 2061 is a potent and specific inhibitor of HCV serine…”
Get full text

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement by Stangier, Joachim, Eriksson, Bengt I., Dahl, Ola E., Ahnfelt, Lennart, Nehmiz, Gerhard, Stähle, Hildegard, Rathgen, Karin, Svärd, Robbyna

“…Dabigatran etexilate is an oral low‐molecular‐weight direct thrombin inhibitor. Following oral administration, dabigatran etexilate is rapidly converted to its…”
Get full text

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C by LARREY, Dominique, LOHSE, Ansgar W, BERGER, Kristi L, MARQUIS, Martin, STEFFGEN, Jürgen, KUKOLJ, George, TREPO, Christian, BRONOWICKI, Jean-Pierre, ARASTEH, Keikawus, BOURLIERE, Marc, CALLEJA, Jose Luis, STERN, Jerry O, NEHMIZ, Gerhard, ABDALLAH, Nasri

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients by Reilly, Paul A., PhD, Lehr, Thorsten, PhD, Haertter, Sebastian, PhD, Connolly, Stuart J., MD, Yusuf, Salim, MD, DPhil, Eikelboom, John W., MB BS, Ezekowitz, Michael D., MD, PhD, Nehmiz, Gerhard, PhD, Wang, Susan, PhD, Wallentin, Lars, MD, PhD

“…Objectives The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of…”
Get full text

Oral bioavailability of dabigatran etexilate (Pradaxa®) after co‐medication with verapamil in healthy subjects by Härtter, Sebastian, Sennewald, Regina, Nehmiz, Gerhard, Reilly, Paul

“…Aim To investigate the effect of the P‐glycoprotein inhibitor verapamil on the pharmacokinetics and pharmacodynamics of dabigatran etexilate (DE). Method In…”
Get full text

Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects by Guth, Brian D., Narjes, Hans, Schubert, Hans‐Dieter, Tanswell, Paul, Riedel, Axel, Nehmiz, Gerhard

“…Aims To characterize the pharmacokinetics of terbogrel, a new combined thromboxane A2 (TxA2) receptor and synthase inhibitor, in healthy human subjects after…”
Get full text

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) by REILLY, Paul A, LEHR, Thorsten, HAERTTER, Sebastian, CONNOLLY, Stuart J, YUSUF, Salim, EIKELBOOM, John W, EZEKOWITZ, Michael D, NEHMIZ, Gerhard, SUSAN WANG, WALLENTIN, Lars

“…The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic…”
Get full text

Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin by Härtter, Sebastian, Koenen‐Bergmann, Michael, Sharma, Ashish, Nehmiz, Gerhard, Lemke, Ute, Timmer, Wolfgang, Reilly, Paul A.

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Dabigatran etexilate is an oral prodrug that is rapidly converted to dabigatran, a direct and reversible thrombin…”
Get full text

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial by Sulkowski, Mark S., Asselah, Tarik, Lalezari, Jacob, Ferenci, Peter, Fainboim, Hugo, Leggett, Barbara, Bessone, Fernando, Mauss, Stefan, Heo, Jeong, Datsenko, Yakov, Stern, Jerry O., Kukolj, George, Scherer, Joseph, Nehmiz, Gerhard, Steinmann, Gerhard G., Böcher, Wulf O.

“…Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing…”
Get full text

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection by Zeuzem, Stefan, Asselah, Tarik, Angus, Peter, Zarski, Jean–Pierre, Larrey, Dominique, Müllhaupt, Beat, Gane, Ed, Schuchmann, Marcus, Lohse, Ansgar, Pol, Stanislas, Bronowicki, Jean–Pierre, Roberts, Stuart, Arasteh, Keikawus, Zoulim, Fabien, Heim, Markus, Stern, Jerry O, Kukolj, George, Nehmiz, Gerhard, Haefner, Carla, Boecher, Wulf Otto

“…Background & Aims Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of…”
Get full text

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial by Sulkowski, Mark S., Bourlière, Marc, Bronowicki, Jean‐Pierre, Asselah, Tarik, Pawlotsky, Jean‐Michel, Shafran, Stephen D., Pol, Stanislas, Mauss, Stefan, Larrey, Dominique, Datsenko, Yakov, Stern, Jerry O., Kukolj, George, Scherer, Joseph, Nehmiz, Gerhard, Steinmann, Gerhard G., Böcher, Wulf O.

“…Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor. In all, 290 noncirrhotic HCV genotype (GT)‐1 patients with prior null…”
Get full text

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients by Sane, Rucha S, Steinmann, Gerhard G, Huang, Qihong, Li, Yongmei, Podila, Lalitha, Mease, Kirsten, Olson, Stephen, Taub, Mitchell E, Stern, Jerry O, Nehmiz, Gerhard, Böcher, Wulf O, Asselah, Tarik, Tweedie, Donald

“…Faldaprevir, an investigational agent for hepatitis C virus treatment, is well tolerated but associated with rapidly reversible, dose-dependent, clinically…”
Get more information

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C by REISER, Markus, HINRICHSEN, Holger, BENHAMOU, Yves, REESINK, Henk W, WEDEMEYER, Heiner, AVENDANO, Cristina, RIBA, Neus, YONG, Chan-Loi, NEHMIZ, Gerhard, STEINMANN, Gerhard G

“…BILN-2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower serum hepatitis C virus (HCV)-RNA…”
Get full text

The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials by Bertsche, Anja, Nehmiz, Gerhard, Beyersmann, Jan, Grieve, Andrew P.

“…In the linear model for cross‐over trials, with fixed subject effects and normal i.i.d. random errors, the residual variability corresponds to the…”
Get full text

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery by Eriksson, Bengt I., Mikuska, Zsolt, Feuring, Martin, Amiral, Jean, Haertter, Sebastian, Stangier, Joachim, Nehmiz, Gerhard, Weitz, Jeffrey I.

“…In adults with moderate renal impairment (creatinine clearance [CrCl] 30–50mL/min) undergoing total hip or knee replacement (THR/TKR), the recommended dose of…”
Get full text

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery by Eriksson, Bengt I, Mikuska, Zsolt, Feuring, Martin, Amiral, Jean, Haertter, Sebastian, Stangier, Joachim, Nehmiz, Gerhard, Weitz, Jeffrey I

“…Abstract Background In adults with moderate renal impairment (creatinine clearance [CrCl] 30–50 mL/min) undergoing total hip or knee replacement (THR/TKR), the…”
Get full text

Response to the letter by D r C hin and co‐workers by Härtter, Sebastian, Koenen‐Bergmann, Michael, Sharma, Ashish, Nehmiz, Gerhard, Lemke, Ute, Timmer, Wolfgang, Reilly, Paul A.

Get full text